Intellia Operating Cycle from 2010 to 2026
| NTLA Stock | USD 13.15 0.75 5.40% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 48.34 | Current Value 76.97 | Quarterly Volatility 81.7750273 |
Check Intellia Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Intellia Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 12.4 M, Interest Expense of 10.3 M or Selling General Administrative of 151.9 M, as well as many indicators such as Price To Sales Ratio of 17.03, Dividend Yield of 0.0 or PTB Ratio of 1.44. Intellia financial statements analysis is a perfect complement when working with Intellia Therapeutics Valuation or Volatility modules.
Intellia | Operating Cycle | Build AI portfolio with Intellia Stock |
Analyzing Intellia Therapeutics's Operating Cycle over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Operating Cycle has evolved provides context for assessing Intellia Therapeutics's current valuation and future prospects.
Latest Intellia Therapeutics' Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of Intellia Therapeutics over the last few years. It is Intellia Therapeutics' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Intellia Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
Intellia Operating Cycle Regression Statistics
| Arithmetic Mean | 81.73 | |
| Geometric Mean | 60.75 | |
| Coefficient Of Variation | 100.06 | |
| Mean Deviation | 49.38 | |
| Median | 60.39 | |
| Standard Deviation | 81.78 | |
| Sample Variance | 6,687 | |
| Range | 353 | |
| R-Value | 0.14 | |
| Mean Square Error | 6,993 | |
| R-Squared | 0.02 | |
| Significance | 0.59 | |
| Slope | 2.27 | |
| Total Sum of Squares | 106,994 |
Intellia Operating Cycle History
About Intellia Therapeutics Financial Statements
Intellia Therapeutics stakeholders use historical fundamental indicators, such as Intellia Therapeutics' Operating Cycle, to determine how well the company is positioned to perform in the future. Although Intellia Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Intellia Therapeutics' assets and liabilities are reflected in the revenues and expenses on Intellia Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Intellia Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 48.34 | 76.97 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Intellia Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intellia Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intellia Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intellia Therapeutics Stock:Check out the analysis of Intellia Therapeutics Correlation against competitors. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intellia Therapeutics. Anticipated expansion of Intellia directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Intellia Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (4.25) | Revenue Per Share | Quarterly Revenue Growth 0.513 | Return On Assets | Return On Equity |
The market value of Intellia Therapeutics is measured differently than its book value, which is the value of Intellia that is recorded on the company's balance sheet. Investors also form their own opinion of Intellia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intellia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intellia Therapeutics' market value can be influenced by many factors that don't directly affect Intellia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Intellia Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Intellia Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Intellia Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.